New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term ...

Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

Sphingosine is a membrane component in all cells and constitutes 25% of the lipid in the myelin sheath. Sphingosine is phosphorylated by ubiquitously expressed sphingosine kinases. S1P regulates ...

Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly reduce brain volume loss compared with placebo. Indirect treatment comparisons reveal varying impacts of disease ...